Moderna Shares Double on Success of mRNA Cancer Vaccine
Analog Devices' profit and revenue soar on accelerating AI data center demand; Unitree Robotics IPOs as mainland China's first humanoid-robot maker. Enterprise AI infrastructure capex remains robust, but OpenAI Q2 revenue disappoints vs Anthropic, signaling LLM market compression and geopolitical shift toward embodied AI.
Moderna Shares Double on Success of mRNA Cancer Vaccine
The result from Merck-Moderna partnership validates years of research into mRNA-based therapeutic cancer vaccines.
Target Raises Fiscal-Year Forecast Again as Turnaround Gains Traction
On the heels of a positive quarter, the retailer now expects sales growth of about 5% this fiscal year.
TJX Raises Guidance Despite Sales Slowdown at T.J. Maxx, Marshalls
Moderna and Merck shares soar on mRNA cancer vaccine
Moderna's and Merck's personalized mRNA vaccine shows real promise against deadly skin cancer melanoma in late stage trial and sends stocks soaring | Fortune
Merck, Moderna Cancer Vaccine Breakthrough Puts 4 ETFs In Focus - Merck & Co (NYSE:MRK)
Healthcare Stocks After Hours: Moderna, Merck Cool Following Cancer Trial Gains - Pfizer (NYSE:PFE), Mode
Moderna Stock Soars on Cancer Vaccine Success
For Moderna, cancer vaccine results ease investor skepticism on its future as stock soars
Moderna shares double after experimental mRNA cancer treatment passes key test
MRNA, BULL, BMNR, MSTR, MRK: 5 Trending Stocks Today - Moderna (NASDAQ:MRNA)
Moderna and Merck cancer vaccine returns ‘landmark’ result in melanoma
‘Breakthrough’ mRNA cancer drug curbs melanoma in large trial
